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Riassunto
Un momento critico nella patogenesi della sclerosi multipla e del suo
modello animale, l’encefalomielite sperimentale autoimmune (EAE), è rappresentato
dall'entrata dei linfociti dai vasi sanguigni nel parenchima del sistema nervoso
centrale  (CNS).  L’attività’  di  ricerca  durante  il  progetto  si  è  focalizzata  sulla
caratterizzazione dei meccanismi molecolari che controllano la migrazione e la
capacità soppressoria dei linfociti CD4
+CD25
+ (cellule T regolatorie) durante l’EAE,
in  quanto  è  noto  che  i  linfociti  T  CD4
+CD25
+  hanno  azione  soppressoria
sull’induzione  delle  malattie  autoimmuni.  Nel  progetto  qui  presentato,  è  stato
analizzato  il  ruolo  della  mucina  P-selectin  glycoprotein  ligand  (PSGL)-1  e  di
fucosiltrasferasi (FucTs) leucocitarie, molecole che controllano la funzionalità del
PSGL-1, nell’azione soppressoria svolta dalle cellule T regolatorie nel contesto delle
malattie autoimmuni del CNS.
Sono stati inizialmente eseguiti esperimenti in vivo di induzione di EAE su
topi WT o che mancano dei geni per le molecole studiate; analizzando l’effetto della
mancanza di PSGL-1 e FucTs sull’induzione dell’EAE mediante immunizzazione
sottocutanea con l’antigene, abbiamo osservato che topi PSGL-1
-/- sviluppano una
malattia più grave rispetto ai WT. Inoltre, cellule T encefalitogeniche ottenute da topi
FucT-VII
-/- e PSGL-1
-/- (induzione passiva), inducono una malattia molto più severa
rispetto a cellule ottenute da topi WT. Allo scopo di spiegare questi risultati, è stata
studiata la proliferazione, la produzione di citochine e la capacità adesiva di cellule T
encefalitogeniche provenienti da topi WT o FucT-VII
-/- e PSGL-1
-/-. I risultati ottenuti
dimostrano che non vi sono differenze significative nell’espressione di molecole
d’adesione e nella produzione di citochine da parte di cellule T autoreattive ottenute
da topi PSGL-1
-/- e FucT-VII
-/-, rispetto a cellule WT. Cellule autoreattive isolate da
topi PSGL-1
-/- e FucT-VII
-/- non mostrano inoltre difetti nella capacità proliferativa
dopo stimolo antigenico.
La nostra attenzione si è spostata sulla possibilità di un coinvolgimento delle
molecole sopra citate nell’azione soppressoria delle cellule T regolatore CD4
+CD25
+.4
Mediante  saggi  di  inibizione  della  proliferazione  è  stata  valutata  la  capacità
soppressoria in vitro di cellule T regolatorie WT e provenienti da topi PSGL-1
-/-,
FucT-VII
-/- e FucT-IV
-/-. Co-culture effettuate con cellule T regolatorie CD4
+CD25
+ e
cellule effettrici (“responder”) CD4
+CD25
-  hanno  indicato  che  la  mancanza  di
espressione di PSGL-1 e FucT-VII porta ad una drastica diminuzione della capacità
soppressoria  sulla  proliferazione  da  parte  delle  T  regolatorie.  Nessun  effetto
significativo è stato osservato in presenza di cellule provenienti da topi FucT-IV
-/-.
Inoltre, la stimolazione delle Tregs con anti-CD3 e IL-2 induce un aumento della
capacità di legame per chimere di P- e E-selectin, recettori endoteliali del PSGL-1;
questa aumentata espressione di PSGL-1 funzionale è accompagnata da una capacità
soppressoria significativamente maggiore sulla proliferazione delle cellule effettrici.
È stata infine valutato l’effetto della mancanza dei geni del PSGL-1 e FucTs sulla
produzione di citochine in saggi Multiplex. I dati dimostrano che la mancanza di
espressione di PSGL-1 e FucT-VII porta ad una netta diminuzione della capacità
soppressoria sulla produzione di citochine pro-infiammatorie da parte delle cellule T
regolatorie. Questi risultati dimostrano quindi un ruolo critico per PSGL-1 e FucT-
VII nell’azione soppressoria svolta dalle cellule T regolatore in vitro.
L’importanza di PSGL-1 e FucT-VII è stata ulteriormente dimostrata anche
in vivo, in quanto cellule T regolatorie isolate da topi PSGL-1
-/-  e  FucT-VII
-/-
mostrano una completa incapacità nel migliorare il decorso clinico della malattia; un
significativo blocco della malattie si è verificato invece utilizzando cellule Treg WT.
Sono  state  successivamente  studiate  le  caratteristiche  migratorie  delle
cellule T regulatorie; allo scopo, sono stati eseguiti esperimenti di microscopia
intravitale, citofluorimetria a flusso e saggi di migrazione in vivo utilizzando linfociti
marcati con glicerolo radioattivo. È stata dimostrata una ridotta abilità migratoria
delle cellule CD4
+CD25
+ derivanti da topi PSGL-1
-/- e FucT-VII
-/- rispetto a cellule
regolatorie WT nel CNS infiammato in corso di EAE. I risultati ottenuti dimostrano
inoltre che le cellule T regolatore presentano una drastica riduzione della capacità di
effettuare  “rolling”  e  adesione  salda  all’endotelio  del  microcircolo  cerebrale
infiammato.5
Nell’insieme i dati ottenuti dimostrano un ruolo centrale del PSGL-1 e della FucT-
VII nell’azione soppressoria svolta dalle cellule T regolatorie. PSGL-1 e FucT-VII
hanno un’importante ruolo sia nel controllo del contatto cellula-cellula necessario per
un’efficace soppressione delle funzioni delle cellule effettrici, che nel controllo del
reclutamento delle Tregs nei vasi cerebrali infiammati in corso di EAE.6
Abstract
CD4+CD25+ regulatory cells (Tregs) represent a lymphocyte population with
the capability to downmodulate immune responses. Here we studied the role of P-
selectin glycoprotein ligand-1 (PSGL-1) and α(1,3) fucosyltransferase-VII (FucT-
VII), a molecule involved in the glycosylation of PSGL-1, in the suppression of EAE
by Tregs. We first observed that PSGL-1
-/- mice developed a more severe EAE, while
encephalitogenic T cells obtained from PSGL-1
-/- and FucT-VII
-/- mice transferred a
more severe disease than WT cells. However, we observed no differences in the
expression of adhesion molecules, cytokine production and proliferation of PSGL-
1/FucT-VII deficient T cells versus WT cells. We then hypothesized a defect in the
suppressor functions of Tregs. Our results showed that PSGL-1 and FucT-VII
deficiency led to a marked decrease of the suppression capacity of Tregs on the
proliferation and production of proinflammatory cytokines. Activation of Tregs
increased the suppression capacity in vitro that correlated with an increased PSGL-1
functionality.  Moreover,  PSGL-1  deficient  Tregs  were  completely  unable  to
ameliorate  EAE  when  compared  to  WT Tregs. Finally, PSGL-1
  and FucT-VII
deficient Tregs lost the ability to migrate into the inflamed CNS. In conclusion our
results demonstrate a key role for PSGL-1 and FucT-VII in the suppression of EAE
exerted by Tregs.7
1. Introduction
1.1 Multiple sclerosis -  general concepts
Multiple Sclerosis (MS) is an inflammatory disease of the central nervous
system, characterized by perivascular evasions of mononuclear cells that include both
lymphocytes and macrophages. This infiltration leads to damage of the myelin sheath
and the underlying axon. Activation of microglia and astrocytes occurs in MS, but it
is secondary to infiltrating lymphocytes. There are two major forms of MS: the
Relapsing-Remitting (RR)-MS is the most common and affects women about twice
as often as men; most RR-MS patients later develop Secondary Progressive (SP)-MS.
The other form is the Primary-Progressive (PP)-MS. In RR-MS, symptoms appear for
several days to weeks, after which they usually resolve spontaneously. After tissue
damage accumulates over many years, patients usually enter the SP-MS, where
preexisting neurological deficits gradually worsen over time; relapses can be seen
during the early stages of SP-MS, but become uncommon as the disease progresses.
10-15% of the patients present a chronic course from the beginning of the disease
(PP-MS form), with gradually worsening manifestations [1; fig.1].
The episodic inflammation that is classic of MS is clearly visualized by
magnetic resonance imaging (MRI) scans of the brain, after administration of contrast
materials such as gadolinium. The duration of enhanced inflammation in individuals
receiving weekly MRI scans is 4-8 weeks, and virtually all lesions enhance in their
earliest phases. When the acute inflammation resolves, it leaves a scar and tissue
damage. The new inflammatory focus can be seen appearing adjacent to the ventricle
and then beginning to resolve. The inflammatory process of MS is associated with a
complex cascade of inflammatory molecules and mediators, including chemokines,
adhesion molecules associated with activated endothelial cell walls and matrix
metalloproteases [2, 3]. It’s not clear which factors are responsible for the different
courses, and there is also heterogeneity in morphological alteration of the brain found
by MRI or histopathological evaluation, e.g., which CNS areas are primarily affected8
and whether a patient responds to treatment. The factors underlying this heterogeneity
are not completely understood, but include a complex genetic trait that translates into
different immune abnormalities and/or increased vulnerability of CNS tissue to
inflammatory insult or reduced ability to repair damage. Also non-genetic factors
seem to be important, such as environmental elements, infectious agents, behavioral
or lifestyle influences and hormonal variables.
The cause of the recurrent inflammation in MS is now generally accepted to
be autoimmune in nature, as a cell-mediated autoimmune attack against the white
matter sheath. In particular, MS is considered a CD4
+ TH1-mediated autoimmune
disease. This view is based on the cellular composition of brain and cerebrospinal
fluid-infiltrating cells and data from experimental allergic encephalomyelitis (EAE),
the main mouse model of the disease. In EAE model, injection of myelin components
into susceptible animals leads to a CD4
+-mediated autoimmune disease that shares
similarities with MS, and can be adoptively transferred by encephalitogenic CD4
+ T
cells into a naïve animal [4, 5]. EAE cannot be transferred by antibodies, and only in
two instance it has been transferred by CD8
+ T cells [6], emphasizing the importance
of CD4
+ T cells.
1.2 Multiple sclerosis immunology
The adaptive immune system can be classified broadly into cellular and
humoral (antibody)-type responses. Among cellular responses, different types or
classes of cellular immune responses have been identified that are essential for
understanding the mechanisms of the inflammatory process in MS and to devising
strategies to control it. Cellular immune responses can be classified as TH1-type or
TH2-type responses, depending on how they differentiate from TH0 precursors [7].
TH1  (or  pro-inflammatory)  cells  generated  when  TH0  cells  differentiate  in  the
presence  of  interleukin  12  (IL-12);  they  are  characterized  by  the  secretion  of
interferon-γ (IFN-γ) and inflammatory mediators, such as tumor-necrosis factor-α
(TNF-α). MS seems to be a cell-mediated autoimmune disease of a TH1 type [Fig.2].9
Anti-inflammatory T-cells include both TH2 cells and T cells that have been classified
as “regulatory cells”. TH2 responses are induced when T cells differentiate in the
presence of IL-4, and TH2-type cells secrete anti-inflammatory cytokines such as IL-4
and IL-10. TH2-type responses are important in fighting parasitic infections, and TH1
and  TH2  responses  may  cross-regulate  each  other.  Another  class  of  T  cell  is
represented by regulatory cells, which can down regulate TH1-type inflammatory
processes. Different types of regulatory cells have been described [8]: TH3 cells act
primarily through the secretion of transforming growth factor-β (TGF-β) and are
preferentially induced at mucosal surfaces [9]; TR1 cells (T-regulatory cell 1) act
primarily through the secretion of IL-10 [10]; CD4
+CD25
+ regulatory cells are T cells
that basally express CD25 (the α-chain of the IL-2 receptor) and exert potent
regulatory function through cell contact and also through secretion of cytokines such
as IL-10 and TGF-β [10]. If MS is a TH1-type cell-mediated autoimmune disease, it
might be possible to regulate the TH1 responses by the induction of regulatory cells
populations.
The induction of TH1-type myelin-reactive cells and their migration into the
nervous system is shown in Fig. 2. It’s postulated that THP (T-cell precursors) are
induced to differentiate into myelin-reactive TH1 cells when an antigen cross-reacting
with a myelin antigen is presented to a T cell by an antigen-presenting cell in the
context of IL-12 and co-stimulatory molecules (molecular mimicry). It is generally
thought that viruses with structures that cross-react with myelin antigens act as cross-
reactive antigens. TH1 T cells that react with myelin antigens, such as proteolipid
protein (PLP), myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein
(MOG), cross the blood-brain barrier, where the myelin antigens are presented to the
T-cells by antigen-presenting cells in the brain (microglia cells), and an inflammatory
cascade is triggered, with the release of inflammatory mediators that cause damage to
the myelin sheath and ultimately the underlying axon.
The MBP isoforms (isoform 4-isoform 14) are, with PLP, the most abundant
protein components of the myelin membrane in the CNS. They have a role in both its
formation and stabilization. The smaller isoforms might have an important role in re-10
myelination of denuded axons in multiple sclerosis. The non-classic group of MBP
isoforms may preferentially have a role in the early developing brain long before
myelination, maybe as components of transcriptional complexes, and may also be
involved in signaling pathways in T-cells and neural cells. Differential splicing events
combined to optional post-translational modifications give a wide spectrum of
isomers,  each  of  them  having  maybe  a  specialized  function.  PLP  is  the  most
represented myeloid protein in the CNS; is 276 aminoacids long and has four highly
hydrofobic regions, which form the transmembrane domain. Another isoform, called
DM20, is generated after alternative splicing of its RNA, and lacks of 35 aminoacids
in a region representing and intracellular loop. In the CNS, PLP acts as a scaffold,
because its extracellular loop define the right membrane-membrane spacing in the
compact myelin. MOG is a minor component of the myelin sheath (about 0.05%); it’s
a tipe I integral membrane protein, with one variable extracellular domain, Ig-like.
The aminoacidic sequence is very conserved between animal species, indicating a
functional biological importance. It seems that MOG is important for the formation
and the compacting of the myelin sheat, and also in the adesiveness in the developed
CNS.
The hypothesis of MS as an inflammatory TH1-type disease is supported by
several observations. First, it has been shown directly by the effects of IFN-γ, the
prototypic TH1 cytokine, which when administered to individuals with MS caused
clinical exacerbations [11]. Second, individuals affected with MS have a TH1 bias, as
indicated by increased concentrations of IL-12 and IL-18, both of which induce IFN-γ
and increase TH1-type chemokine receptors expression [12]. Last, IL-12-secreting
cells in the peripheral blood are linked to inflammation in the CNS: increased
numbers  of  IL-12-secreting  cells  in  the  blood  are  associated  with  gadolinium
enhancement on MRI imaging, and cyclophosphamide decreases the number of IL-
12-secreting cells, which is linked to clinical response. In addition to IL-12, it has
been  shown  recently  that  osteopontin  is  important  in  TH1  differentiation  in
autoimmune demyelization diseases. The most widely used immuno-modulatory drug
in MS, IFN-β, seems to have two broad mechanisms of action: it decreases IFN-α11
secretion by cells in the peripheral blood and blocks the migration of T cells across
the blood-brain barrier [13].
One  of  the  primary  animal  models  for  MS,  experimental  autoimmune
encephalomyelitis (EAE), is induced by immunizing different mouse or rat strains
with a myelin auto antigen (such as MBP, PLP or MOG) given in complete Freund's
adjuvant,  which  induces  a  TH1-type cell-mediated response against the myelin
antigen. In EAE, myelin-reactive TH1-type CD4
+ T cells migrate from the periphery
into the CNS, where they also initiate a cascade of immune-mediated damage [Fig.2].
In animals, EAE can also be induced by the adoptive transfer of TH1-type CD4
+ cells
specific for one of the myelin proteins.
1.3 Lymphocyte recruitment in inflamed tissues
Lymphocyte migration into brain and spinal cord represents a critical event in
the pathogenesis of MS and its animal model, EAE. However, the mechanisms
controlling the recruitment of lymphocytes to the central nervous system via inflamed
brain venules are poorly understood, and therapeutic approaches to inhibit this
process are consequently few. In 1987–1990, a number of discoveries came together
and led us to propose a quite speculative general model [14] to explain the targeting
of lymphocytes as well as other leukocytes from the blood. The key elements were a
common process involving three or more steps – rolling, chemo-attractant activation
of integrin or other inducible adhesion molecules, and firm adhesion (arrest or
sticking) – in which substitution of interchangeable receptor-ligand pairs at each step
provided a combinatorial mechanism for generating specificity and diversity in
leukocyte endothelial cell recognition and hence recruitment [Fig.3].
Molecular specificity in the targeting of leukocytes at sites of inflammation is
mediated by selectins, integrins, and immunoglobulin gene super family [15]. A
fourth class of glycoproteins are the mucins, that serve as glycoprotein ligands for the
selectins [16]. Based on in vitro and in vivo observations, leukocyte recruitment may
be described as a sequential process having at least three distinct adhesive events.12
Leukocytes are captured by the inflamed endothelium from the blood stream,
by tethering via constitutively expressed leukocyte selectin denoted as L-selectin
(CD62L), which recognize glycoprotein ligands, like the Peripheral lymph Node
Adressin  (PNAd)  [17],  up-regulated  on  cytokine-activated  endothelium.  The
capturing is also supported by leukocyte PSGL-1 (P-selectine glycoprotein ligand-1),
which binds to the P-selectin (CD62P) expressed on the inflamed endothelium [18].
P-selectin on endothelial cells is the primary adhesion molecule for capture and the
initiation of the second step, the rolling [19]. The selectins mediates in fact also the
rolling process, where P-selectin is the most important molecule involved. P-selectin
can  support  both  capture  and  rolling  in  the  absence  of  L-selectin. Upon pro-
inflammatory stimulation, P-selectin is rapidly surface-expressed on the venular
endothelium, and  it  makes  the  endothelium "sticky"  to  leukocytes. PSGL-1  is
constitutively  expressed  on monocytes,  eosinophils,  and  neutrophils;  it  has  a
glycosylation pattern allowing it to bind to endothelial P-selectin. As a result, the
leukocyte rolls along the endothelium. During rolling, bonds are formed at the
leading edge of the rolling cell and broken at the trailing edge. Leukocyte integrins
initially remain in their resting state, and endothelial immunoglobulins remain at
control levels. Leukocyte rolling is also supported by the endothelial selectin E-
selectin (CD62E), which is thought to be responsible for slow rolling interactions
below 5mm/s and possibly the initiation of firm adhesion [20]. E- and P-selectin are
up-regulated on the plasma membrane in response to cytokine or thrombin and
histamine stimulation, respectively. These two selectins can bind PSGL-1 and L-
selectin expressed by leukocytes. The carbohydrate and epitope specificity of selectin
recognition has been determined by blocking adhesion with mAbs to each selectin,
recombinant soluble selectins, and target polysaccharides. These interventions are
effective  in  blocking  tethering  and  rolling  in  vitro,  and  they  can  inhibit  the
accumulation  of  PMNs  at  sites  of  inflammation  in  animal  models  of  acute
inflammation [16]. The requirement for selectins in primary cell capture and rolling
has also been confirmed in transgenic mice deficient in L-selectin, E-selectin, P-
selectin or PSGL-1 [21, 22]. In addition to selectin-mediated rolling, Very Late
Antigen-4 (VLA-4 or α4β1 integrin), an adhesion receptor of the integrin family that13
binds to the Vascular Cell Adhesion Molecule-1 (VCAM-1), has also been found to
mediate rolling of certain leukocyte subsets [23].
Rolling along the endothelium is thought to allow sufficient time for eliciting
the activation and the clustering of leukocyte integrins, which then bind to their
counter receptors, resulting in a shear-resistant firm adhesion. In this context, all three
selectins exhibit the capacity to become clustered following ligand binding, which
correlates  with  transmembrane  signaling  of  a  diverse  set  of  pro-inflammatory
functions, including membrane upregulation of integrins into high-affinity clusters on
leukocytes and clustering of E- and P-selectin on rigidified membrane domains of the
endothelium [24].
The last step, the firm adhesion, is initiated by the stimulatory effects exerted
by growing number of chemokines and other mediators: after rolling, leukocytes
become activated and attach to the endothelium through adhesion of β2-integrins,
including the Lymphocyte Function-associated Antigen-1 (LFA-1 or αLβ2 integrin)
and  the  Macrophage  Antigen  1  (Mac-1  or  αMβ2  integrin), to immunoglobulin
superfamily members such as Intercellular Adhesion Molecule-1 (ICAM-1) [25]. In
addition, β1-integrins and their ligands, such as the VLA-4/VCAM-1 pair, are
involved  in  leukocyte-endothelial  cell  binding.  Pro-inflammatory  cytokines,
including IFN-γ, TNF-α and IL-1, can increase T cell localization to inflammatory
sites  through  induction  of  ICAM-1  and  VCAM-1  [26].  Once  firmly  adhered,
leukocytes can transmigrate through the endothelium in the inflamed tissue; this
process is probably mediated by the same integrins involved in the adhesion cascade,
with the help of such chemo-attractive signal from the tissue.
1.4 Selectins structure: importance of glycosylating enzymes
Selectins  are  a  family  of  three  C-type lectins (glycoproteins) expressed
exclusively by bone-marrow-derived cells and endothelial cells. Their structure is
modular, with an amino-terminal lectin domain, followed by an EGF-like domain,
several consensus repeats with homology to complement regulatory proteins, a single14
transmembrane domain, and
 a short carboxy-terminal cytoplasmic tail [27]. The main
physiological function of all selectins is in mediating leukocyte adhesion under flow,
but both selectins and their ligands also have signaling functions [28]. Selectins
mediate cell-cell adhesion
 through interactions of the lectin domain with specific
glyco-conjugate
 ligands. Like other mammalian lectins, the selectins bind selectively,
but  with  low  affinity,  to  particular  oligosaccharides.  All selectins
  bind  to  the
tetrasaccharide sialyl Lewis x (sLe
x; NeuAc2,3Gal1,4[Fuc1,3]GlcNAc) and its isomer
sialyl Lewis
 a (sLe
a; NeuAc2,3Gal1,3 [Fuc1,4]GlcNAc). L- and P-selectins, but not
E-selectin, also bind to particular sulfated carbohydrates, such
 as heparan sulfate,
which lack sialic acid and fucose. However, selectins bind with higher affinity or
avidity
  to  only  a  little  number  of  glycoproteins.  Most  of  these  are  mucins,
glycoproteins
 with multiple Ser/Thr-linked oligosaccharides (O-glycans) and
 repeated
peptide motifs. A key issue is whether
 any of these molecules mediates biologically
relevant interactions with selectins. These perspectives focused the attention on
PSGL-1, a sialomucin with the most clearly
 defined function as selectin ligand [29].
A cDNA encoding PSGL-1 was subsequently isolated from a human HL-60
cell library by expression cloning, using COS cells panned on immobilized P-
selectin. Functional expression
 of PSGL-1 in COS cells required co-transfection with
a  1,3  fucosyltransferase,
  confirming earlier observations that 1,3 fucosylation of
surface glycoproteins is required for binding
 to P- and E-selectin [30]. PSGL-1 is
constitutively expressed on T cells, but in a non-functional form; it must be modified
with a 2,3-linked sialic acid and a 1,3-linked fucose in order to bind P- and E-selectin.
Two α(1,3) fucosyltransferases (FucT), FucT-VII and FucT-IV, are expressed in
leukocytes and endothelial cells and catalyze the final reaction in selectin ligand
biosynthesis,  the  addition  of  fucose  to  sialylated  precursors  [31].  PSGL-1  is
fucosylated by both FucT-VII and FucT-IV, but FucT-VII is principally responsible
for efficient PSGL-1 interactions with endothelial selectins. Expression of Cutaneous
Lymphocyte Antigen (CLA), a FucT-VII-dependent carbohydrate modification of
PSGL-1, is closely correlated with interactions between PSGL-1 and E-selectin.
FucT-VII is essential for the synthesis of all selectins ligands in T cells; its expression
absence by naïve T cells explains the lack of selectins ligands on them. TH1 cells15
have high levels of expression of FucT-VII and selectins ligands, whereas the low
levels of FucT-VII in TH2 cells correlate with low levels of selectins on these cells.
For this reason, TH1 cells, but not TH2 cells, are able to bind to P-selectin and E-
selectin [32].
1.5 CD4
+CD25
+ regulatory T cells: migration patterns
CD4
+CD25
+ regulatory T cells (Tregs) are a subset of suppressor T cells that
function regulating the immune responses. A large body of data demonstrates that
they are important in the maintenance of immunological homeostasis and self-
tolerance. In several animal models it has been convincingly demonstrated the
suppressive activity of Tregs in autoimmune and allergic diseases, and in allograft
rejection. Indeed, it has been clearly shown that Tregs are able to suppress EAE in
various experimental models, including MOG35-55-induced EAE in C57Bl/6 mice.
Moreover, it has been shown a significant decrease in the effector function of
CD4
+CD25
high  regulatory  T  cells  from  the  peripheral  blood  of  MS  patients  as
compared with healthy donors [33].
Tregs appear to be generated as a unique lineage of T cells within the thymus,
suggesting  that  self-reactive  Tregs  are  there  generated  during  normal  cell
development. Also peripheral induction of suppressive CD4
+ T cells from naïve T
cells has been reported. These two populations are very similar; their development is
mainly controlled and programmed by the transcription factor Foxp3, which is the
universal master switch for the generation and the activity of these cells [34].
Thymus-derived and peripheral-induced Tregs are functionally indistinguishable, and
are able to inhibit the proliferation and the activation of naïve T cells. For all these
evidences, the enhancement of the number and activity of peripheral Tregs seems to
represent an obvious goal for the treatment of autoimmune diseases.
Where Tregs act and how they migrate in vivo has hardly been studied so far.
L-selectin, which is required for entry into lymph nodes, has been found on the
majority of CD4
+CD25
+ Tregs. Other papers report the presence of receptors for16
inflammatory chemokines and increased levels of adhesion molecules on regulatory
subsets, suggesting that these cells are able to enter inflamed tissues and might act
directly at sites of inflammation. However, a comprehensive analysis on trafficking
properties of Tregs in vivo is still lacking. It has been recently shown that the integrin
αEβ7 subdivides the Treg compartment into αE
- and αE
+ Tregs, which largely differ in
their in vivo suppressive activity and in the expression of adhesion molecules and
chemokine receptors. αE
-  Tregs displayed a naïve-like phenotype and efficiently
migrated into lymph nodes, fitting to their high L-selectin expression and their high
responsiveness towards CCR7 ligands. They lacked suppressive capacity under acute
inflammatory conditions, but turned out to be most potent at suppressing naïve CD4
+
T-cell proliferation within the lymph node. On the other hand, αE
+ Tregs showed
increased frequencies of E/P-selectin ligands expression combined with a strong
down-regulation of L-selectin and high responsiveness towards several inflammatory
chemokines. These characteristics are associated with a high suppressive potential in
varius inflammation models, thanks to their efficient entering into inflamed tissues,
and a poor capability to migrate into lymph nodes. For these reasons, the αE
+, but not
αE
-, subsets of Tregs are also able to bind P- and E-selectin, and, when transferred in
vivo, preferentially migrate in inflamed joints and block antigen-induced arthritis in
C57Bl/6 mice. Moreover, it has been recently shown that also regulatory IL-10-
producing CD4
+ T cells bind E- and P-selectin with higher frequency when compared
to TH1 and TH2 cells and are able to migrate in inflamed lung, suggesting that
functional PSGL-1 might be used by various Treg subpopulations to migrate in sites
of inflammation. Supporting this hypothesis, αE
+  Tregs from FucT-VII deficient
mouse, which lack E/P-selectin ligands, fail to migrate into inflamed sites and cannot
suppress the skin inflammation; this demonstrates that immigration into inflamed
sites is a prerequisite for the resolution of inflammatory reactions in vivo, because
these selectin ligands merely regulate entry into inflamed tissues [35].
These data demonstrate that different populations of Tregs have the capability
to enter sites of inflammation and exert their suppressive activity directly into the site
of ongoing immune reaction [Fig.4]. In this project, will be studied the importance of17
FucT-VII and PSGL-1 in suppressive activity of Tregs toward antigen-specific TH1
cells; moreover, it will be analyzed the migration pattern of Tregs lacking these two
molecules.18
2. Materials and Methods
Mice
6- to 8-weeks-old C57BL/6J female mice were used as WT controls. FucT-VII
-
/-, FucT-VII
-/-, FucT-IV
-/-/FucT-VII
-/- and PSGL-1
-/- mice were obtained from J.B.
Lowe (FucTs
-/-; Case Western University, School of Medicine, Cleveland) and R.P.
McEver (PSGL-1
-/-; University of Oklahoma, Health Science Center). Deficient mice
were on a C57BL/6 genetic background (backcrossed for at least 9 generations). Mice
were housed and used according to current European Community rules.
Active EAE induction
Mice were immunized sub-cutaneously in the flanks with 200 µg of myelin
oligodendrocyte glycoprotein (MOG)35-55 peptide in 100 µl emulsion consisting of
equal volumes of PBS and complete Freund adiuvant, supplemented with 8 mg/ml of
Mycobacterium tuberculosis (strain H37Ra; Becton-Dickinson). Mice received 20 ng
of pertussis toxin (Alexis biochemicals) intra-venously at the time of immunization
and 48 h later. Clinical scores were recorded daily according to the following scale:
0= no disease; 1= tail weakness; 2= posterior legs weakness; 3= one posterior leg
paraplegia; 4= complete posterior paraplegia; 5=paraplegia with forelimb weakness
or paralysis; 6= moribund or dead animals.
Production of MOG35-55 T cell lines and induction of passive EAE
C57Bl/6J 8- to 10-weeks-old female mice were immunized with 100 µl of
emulsion/mouse containing 300 µg MOG35-55 peptide in CFA supplemented with 0.8
mg of Mycobacterium tuberculosis. After 10-12 days, mice were sacrificed and MOG
specific T cell lines were produced from spleens and draining lymph nodes. Cells
were then cultured in tissue culture medium in the presence of 20 µg/ml MOG35-55
peptide and 1 ng/ml murine IL-12. After three days, cells were washed three times in
D-PBS 1x and injected intra-venously  in  naïve  recipients,  in  a  volume  of  0.5
ml/mouse containing 3 - 4 x 10
6 blast cells. Pertussis toxin (150 ng) was administered
intra-venously in the same day of cell transfer and two days later.19
ELISA assay
The following cytokines were tested on proliferation assay supernatants:
mouse TNF-α, mouse IFN-γ and mouse IL-4. NUNC Maxi Sorp plate was coated
with anti-mouse cytokine antibody and incubate overnight at 4° C. Plate was washed
once with wash buffer (PBS/0.1 % tween 20) by using the automated ELISA plate
washer and blocking buffer (PBS 10% FC) was added to each well and incubated for
1 h. at 37° C. Samples were adequately diluted in assay buffer (PBS 5% FC), 100
µl/well and incubated all together with standard ON at 4° C. Plate was washed six
times with wash buffer. Anti-mouse cytokine biotinylated antibody was incubated for
1 h at room temperature. Plate was washed six times with wash buffer. Streptavidin-
HRP was added and incubated for 45 minutes at room temperature. Developing
reaction was made with TMB and stopped with 1M H2SO4. The optical density of
each well was determined immediately. Standard curve was created by reducing the
data using computer software capable of generating a four parameter logistic (4-PL)
curve-fit.
Flow cytometry for surface staining
The following antibodies and reagents were used for cell surface staining: rat
anti-mouse IgG hybridoma culture supernatants PS/2 (anti-VLA-4), MJ64 (anti-
CD44), Mel-14 (anti-L-selectin), Tib-213 (anti-LFA-1), 4RA10 (anti-PSGL-1); rat
IgG isotype; Goat anti-rat IgG PE; anti-CD4 PE, anti-CD8 PE, anti-CD19 FITC, anti-
CD3 FITC; rat IgG isotype FITC; rat IgG isotype PE; hamster IgG isotype. Flow-
cytometric analysis was performed on a BD FACSCan using CellQuest 3.3 software.
E- and P-selectin chimeras binding assays
The  extracellular  domain  of  mouse  E-  and  P-selectin  was  fused  to  the
carboxy-terminal 6X histidine tagged Fc region of human IgM via a polypeptide
linker. The chimeric protein was expressed in a mouse myeloma cell line, NS0.
Cells were stained by combining 5x10
5 cells with selectin chimeras in a total
volume of 100 µl for 30 minutes at 4° C. Following incubation, the cells were washed20
once in 400 µl of DMEM, resuspended in 100 µl of PE-labeled goat anti-human IgM
secondary antibody and incubated for 20 minutes at 4° C. The cells were pelleted and
resuspended  in  fresh  DMEM  immediately  before  FACS  analysis.  Nonspecific
staining  was  established  by  addition  of  EDTA  (10mM)  to  staining  reactions
condicted with the selectin chimeras.
Production of CD4
+CD25
+ Tregs
Peripheral lymph nodes and spleens were harvested from 8- to 10-weeks-old
C57Bl/6J mice, dissociated mechanically and washed twice after treatment with lysis
buffer and antibiotic solution. Cells were separated by magnetic cell sorting in a two-
step procedure (all reagents from Miltenyi Biotec). Briefly, CD4
+ cells were first
enriched by depletion of non-CD4
+ T cells by indirect labeling with Biotin-Antibody
cocktail and Anti-Biotin MicroBeads. In parallel, cells were labeled with anti-CD25-
PE antibody. The cell suspension was then loaded onto a column placed in a
magnetic field, and the magnetically labeled non-CD4
+  cells  are  retained  in  th
column, whereas the unlabeled CD4
+ cells that run through will be collected and
labeled in a second step with anti-PE MicroBeads. Subsequently, CD4
+CD25
+ cells
were isolated by loading the cell suspension onto a second column and collecting the
cell fraction, which is retained in the column, by immediate flushing out. The purity
of the obtained cell population (usually >85%) was determined by FACS analysis of
the PE-labeled fraction.
T regulatory inhibition of proliferation assays
CD4
+CD25
+ Tregs were co-cultured with CD4
+CD25
- responder cells using
the following ratios CD4
+CD25
-/CD4
+CD25
+ T cells: 1/0.06; 1/0.12; 1/0.25; 1/0.5. A
fixed number of CD4
+CD25
- cells (1x10
5/well) were cultured in U bottom 96-well
microtiter plates in the presence of 1 µg/ml  anti-CD3  mAb  and  2x10
5  APCs
(irradiated splenocytes) for 4 days. Proliferation control was performed using, in the
same well, 1x10
5 of CD4
+CD25
- T cells in the presence of APCs and in absence of
Tregs. [
3H]-thymidine (1 µCi/well) was added in each well 18 h before the cultures21
were terminated. [
3H]-thymidine uptake was determined by using a Microplate
Scintillation Counter (Perkin-Elmer).
For stimulated Tregs, CD4
+CD25
+ cells were coltured in a 48 wells plate with
2x10
6 Tregs/well in the presence of anti-CD3 5 µg/ml and IL-2 100 U/ml, in 1 ml of
total  volume,  for  3  days.  Cells  are  then  collected  and  the  proliferation  assay
performed as described before.
Bio-plex analysis of cytokine production
Supernatants from inhibition of proliferation assays were collected before the
addiction of [
3H]-thymidine, and stored at –0° C for short times. At the time of
analysis, samples were defrosted and treated with the Bio-Plex cytokine assay (Bio-
Rad), which uses the multiplexing technology of Luminex Corp. In this system, every
sample’s cytokine was firstly bound (reaction in a microplate well) with polystyrene
beads internally dyed with differing ratios of two spectrally distinct fluorophores.
Each fluorophore can have any of 10 possible levels of fluorescent intensity, thereby
creating a family of 100 spectrally addressed bead sets. The binding is possible
thanks to mAbs conjugated with the beads; any bead is conjugated with a mAb
specific  for  only  one  target  cytokine.  After  that,  the  samples  was  added  with
monoclonal- biotinylated antibodies, specific for the several cytokines, in order to
form a capture sandwich immunoassay. Finally, streptavidin-PE antibody was added.
Samples so prepared were analyzed with Bio-plex system (Bio-Rad; powered
by  Luminex  xMAP
TM technology). In this instrument, samples are illuminated
contemporaneously with a red diode "classification" laser (635 nm) and a green
"reporter" laser (532 nm). Beads are sorted thanks to the Bio-Plex Manager software,
which correlates each bead set (his dye) to the assay reagent that has been coupled to
it. On the other hand, the amount of green fluorescence is proportional to the amount
of analyte captured in the immunoassay. Extrapolating to a standard curve allows
quantification of each analyte in the sample. With this system we evaluated the
concentration of TNF-α, IL-1b, IL-2, IL-4, IL-5, IL-10, GM-CSF and IFN-γ in the
supernatants collected in the inhibition of proliferation experiments.22
Migration assay with [
3H]-glycerol
Tregs isolated as described before were cultured in a 48 well plate, in 1 ml of
total volume (x TK-1 medium) containing 2x10
6 Tregs + 25 µCi/ml of [
3H]-glycerol
(GE Healthcare). Cells were collected after 18 h, washed 3 times with D-PBS 1x, re-
suspended in 500 µl of D-PBS 1x and injected in mice previously immunized. Mice
were sacrificed after 24 h and perfused with D-PBS 1x + heparin 5 U/ml; brain,
spinal cord, liver, spleen, lymph nodes, thymus and blood (100 µl) were collected.
Organs  were  weighted,  put  in  700  µl  of  water  and  sonicated  with  Sonoplus
(BANDELIN electronic). Blood was mixed with 500 µl of PBS + heparin 10 U/ml +
dextran 1%, in order to precipitate red cells. After 30’, supernatant was collected and
centrifuged 5’ x 400g. The pellet obtained was re-suspended in 500 µl of water. All
the samples so obtained were added with 17 ml of scintillator liquid (Ultima Gold
from Perkin-Elmer); the radioactivity was red with a β-counter (Perkin-Elmer).
Intravital microscopy
Tregs were isolated from WT, FucT-VII
-/- orPSGL-1
-/- mice as previously
described, and stimulated for 3 days in a 48 wells plate: 1 ml/well with 2x10
6 Tregs +
anti-CD3 5 µg/ml and IL-2 100 U/ml. At the time of the experiment, they were
collected, washed 2-3 times with D-PBS and re-suspended in 1 ml of DMEM
medium + HEPES 20 mM + FCS 5% (pH 7.05). Cells were labeled with red
CMTMR (5-(and-6)-(((chloromethyl)benzoyl)amino)tetramethylrhodamine) or green
CMFDA (5-chloromethylfluorescein diacetate) (Molecular probes).
Wild type C57Bl/6 mice were injected intraperitoneally with 12 µg LPS 5-6
hours  before  starting  the  intravital  experiment.  After  this  time,  animals  were
anesthetized and a heparinized PE-10 catheter was inserted into the right common
carotid artery toward the brain. In order to exclude non-cerebral vessels from the
analysis, the right external carotid artery and pterygopalatine artery, a branch from
the internal carotid, were ligated [Fig.5A]. Then, the scalp will be reflected and a 24
mm x 24 mm coverslip will be applied and fixed with silicon grease. A round camera
with 11 mm internal diameter will be attached on the coverslip and filled with water23
as previously described in our group [Fig.5B] (Constantin et al., Immunity 2000;
Piccio et al., 2002; Pluchino et al., Nature 2005).
The preparation was placed on an Olympus BX50WI microscope and a water
immersion objective with long focal distance (focal distance 3.3 mm, NA 0.5 ∞) was
used. Blood vessels were visualized through the bone by using fluorescent dextran
[Fig.5C]. 2-3x10
6 fluorescently labeled cells/condition, resuspended in PBS 1x, were
slowly injected into the carotid artery by a digital pump. The images were visualized
by using a silicon-intensified target videocamera (VE-1000 SIT) and a Sony SSM-
125CE monitor, and recorded employing a digital VCR [Fig.5D] (Constantin et al.,
Immunity 2000).
Image analysis
Video analysis was performed by playback of digital videotapes. Vessel
diameter  (D),  haemodynamic  parameters  and  the  velocities  of  rolling  were
determined by using a PC based system. The velocities of ≥ 20 consecutive freely
flowing cells/venule were calculated, and from the velocity of the fastest cell in each
venule (Vfast), we calculated the mean blood flow velocities (Vm): Vm=Vfast/(2-ε
2).
The wall shear rate (WSR) was calculated from WSR=8xVm/D (s
-1), and the wall
shear stress (WSS) acting on rolling cells was approximated by WSR x 0.025
(dyn/cm
2), assuming a blood viscosity of 0.025 Poise. Lymphocytes that remained
stationary  on  venular  wall  for  ≥ 30 s were considered adherent. At least 140
consecutive cells/venule were examined. Rolling and firm arrest fractions were
determined as the percentage of cells that rolled or firmly arrested within a given
venule in the total number of cells that entered that venule during the same period.
Statistics
Quantitative data are given as mean values ± S.D. or S.E.M. A two-tailed
Student's t test was employed for statistical comparison of two samples. Multiple
comparisons were performed employing Kruskall-Wallis test with the Bonferroni24
correction of P. Velocity histograms were compared using Mann-Whitney U-test and
Kolmogorov-Smirnov test.25
3. Results
3.1 Autoreactive T cells from FucT-VII
-/- and PSGL-1
-/- mice induce severe EAE
As previously reported by our group, α(1, 3) fucosyltransferase (FucT)-VII
and PSGL-1 are critical for lymphocyte recruitment in inflamed tissues (Piccio et al.,
J.  Immunol.  2005).  Thus  we  expected  to  observe  a  reduced  EAE  severity  by
transferring autoreactive T cells obtained from mice deficient of these molecules or
by inducing active EAE in mice deficient mice. In contrast with our expectations, we
observed that PSGL-1 deficient mice develop a more severe EAE comparing to WT
mice (Fig. 6). In addition, mice transferred with cells from PSGL-1
-/-  mice  [8
mice/condition; Fig. 7] developed a more severe disease. Similar results were
obtained with FucT-VII
-/- MOG-specific donor cells [8 mice/condition; Fig. 8], when
compared with mice receiving WT cells. Encefalitogenic T cells obtained from FucT-
IV
-/-  animals  induced  a  disease  comparable  to  WT  cells.(the  data  were   not
statistically significant and were  variable in the several experiments [P=0.43; Fig. 8].
3.2 FucTs and PSGL-1 deficiency have no effect on the proliferation, adhesion
molecule expression and pro-inflammatory cytokine production of MOG35-55 T cells
In order to explain the increase of the disease severity due to FucT-VII or
PSGL-1  deficiency,  we  asked  whether  the  proliferative  response  after  antigen
stimulation  is  modified  in  FucTs  or  PSGL-1  deficient  MOG35-55  T  cells.  No
statistically significant differences were observed between WT and PSGL-1 or FucTs
deficient cells [Fig. 9]. We further analyzed the cytokine production of MOG35-55
autoreactive cells in FucTs or PSGL-1 deficient autoreactive T cells. For this purpose
we  performed  ELISA  on  cell  supernatants  obtained  from  proliferation  assay
experiments. No statistically significant differences were observed in the production
of IFN-γ and IL-4 between WT and FucTs/PSGL-1 deficient cells [Fig. 10]. As
expected, the production of IL-4 was low consistent with the TH1 phenotype of26
MOG-specific encephalitogenic T cells. Moreover, no significant differences were
obtained when we measured TNF-α production (data not shown).
We also analyzed the expression of adhesion molecules on WT and PSGL-1
-/-,
FucT-VII
-/-  and FucT-IV
-/- MOG35-55 T cells; as shown for the proliferation and
cytokine production, no significant differences in the expression of LFA-1, VLA-4,
L-selectin, and CD44 were observed (data not shown).
3.3. Stimulation of regulatory T cells with anti-CD3 mAb and IL-2 increases
adhesive and suppressor capacities of CD4+CD25+ T cells in vitro
The results presented above gave no apparent explanation on why T cells
lacking PSGL-1 or FucT activity induce a more severe disease or on the increased
severity in mice deficient in PSGL-1. Proliferation, adhesion molecule expression and
the production of cytokines by autoreactive lymphocytes are similar in WT and
PSGL-1/FucTs deficient cells. We next hypothesized some functional defects in the
suppressor activity of CD4
+CD25
+ regulatory T cells.
It is widely accepted that Tregs require cell-cell contact in order to exert
inhibitory effects on activated T cells. We have first set up a proliferation assays in
order to test the suppressive effect of CD4
+CD25
+ T cells on the proliferation of
CD4
+CD25
- cells. Recently, it has been shown that pre-culture of CD4
+CD25
+ T cells
for 1-3 days in the presence of plate-bond anti-CD3 (5 µg/ml) mAb and high doses of
IL-2 or IL-4 induces the production of more potent suppressor cells in vitro. Thus, we
compared the activity of naïve versus stimulated Tregs.
We initially asked if activation of CD4
+CD25
+ T cells modifies their adhesive
capability. To this purpose, we compared the expression of adhesion molecules and
the ability to bind E- and P-selectin chimeras in functional assays by using flow
cytometry. The binding of selectin chimeras measures the functionality of PSGL-1.
Our results indicate that after 3 days of activation, no significant differences were
observed in the expression of α4 integrins, LFA-1, PSGL-1 on activated Tregs when
compared  with  naïve  Tregs,  whereas  L-selectin  increased  after  stimulation.27
Interestingly, the capacity to bind P- and E-selectin increased significantly after
activation, suggesting that PSGL-1 became functional and able to bind its counter-
ligands  after  Treg  activation  [Tab.  I].  These  data  also  suggest  that  activated
CD4
+CD25
+ T cells may have increased ability to migrate into sites of inflammation
in which endothelium expresses endothelial selectins.
We next studied whether activation of CD4
+CD25
+ T cells modifies also their
suppressor capacity. To this purpose, we performed proliferation assays using co-
cultures naïve CD4
+CD25
+ cells or activated CD4
+CD25
+ cells plus CD4
+CD25
- cells
(responder/effector cells). Different ratios between Tregs/effector cells were used (see
Figure legend 11). Our results showed that after 3 days of activation, Tregs increased
their inhibitory capability on CD4
+CD25
- proliferation when compared with naïve
Tregs inhibition [Fig. 11]. These results reveal that the increased functionality of
PSGL-1 is associated with an increase of the immunosupression ability of Treg.
3.4 Anti-L-selectin and anti-PSGL-1 blocking antibodies revert immunosupressive
capability of Tregs
In  order  to  confirm  that  PSGL-1  and  FucTs  participate  to  mechanisms
involved in the suppression of autoimmune attack against brain antigens and in order
to understand which are the adhesion molecules involved in the cell-cell contact, we
performed proliferation assays in the presence of monoclonal blocking mAbs. The
following mAbs were used: rat anti-mouse IgG hybridoma culture supernatants Mel-
14 (anti-L-selectin), 4RA10 (anti-PSGL-1) and PS/2 (anti-VLA-4) as a negative
control. The results indicate that both L-selectin that PSGL-1 are involved in the cell-
cell contact necessary for the suppressor activity exerted by Tregs [Fig. 12].
3.5 FucTs and PSGL-1 deficient Tregs show a defect in the suppressor activity
We  next  studied  the  effect  of  PSGL-1  and  FucTs  deficiencies  on  the
suppression of proliferation by CD4CD25+ T cells. We performed co-cultures using
different ratios of Tregs/effector cells as described above. We first controlled the28
expression of Foxp3 in all Treg populations. We observed a similar expression of
Foxp3  in  WT  and  PSGL-1/FucT  deficient  Tregs  suggesting  that  the  potential
reduction in the suppressor activity is not due to a decrease in Foxp3 expression
(results not shown). Data obtained using naïve Tregs showed that CD4
+CD25
+ cells
from FucT-VII deficient mice exerted significantly less inhibitory effect on the
proliferation of wild type CD4
+CD25
- responder cells [Fig.13A]. Interestingly, when
co-cultures were made with both Tregs and responder cells deficient of FucT-VII, we
observed that inhibition of proliferation by Tregs was dramatically reverted [Fig.
13C]. No significant role was observed for FucT-IV, when deficiency either in Tregs
or in CD4
+CD25
- responder cells or both [Fig.13B]. PSGL-1 deficiency on responder
cells, but not on Tregs, partially reverted the inhibitory effect of Tregs on the
proliferation  [Fig.  13D].  Taken  together,  these  results  suggest  that  glycans
fucosylated on both Tregs and responder cells are involved in the suppression of
proliferation. Notably, these data were confirmed in proliferation assays performed
with antiCD3/IL-2 stimulated WT and PSGL-1/FucT deficient Tregs (data not
shown).
3.6 FucT-VII activity has an important role in Treg-mediated suppression of
cytokine production
We next asked whether Tregs are able to suppress the production of cytokines
by CD4
+CD25
- responder cells. We focused our attention on two different ratios
Teff/Tregs, 1/0.12 and 1/0.06, and evaluated the release of IL-2, IL-4, IL-5, IL-10,
GM-CSF, IFN-γ, TNF-α and IL-1β in the supernatans samples using the Multiplex
system from BioRad (see “Material and methods”). FucT-VII deficiency in Tregs and
effector T cells led to a reduction of the inhibitory effect on the production of pro-
inflammatory  cytokines  such  as  GM-CSF,  IFN-γ and IL-1 [P<0.01. Fig. 14A].
Interestingly, we observed no reduction of the inhibitory effect on the production of
TH2 and anti-inflammatory cytokines such as IL-4, IL-5 and IL-10 [Fig. 14B]. These
results support the data obtained in proliferation assays and show an important role29
for FucT-VII expression on both Tregs and Teff cells [Fig. 14A and B]. IL-1β and
TNF-α were produced in very low amounts in these experiments, and no significant
differences were found between KO and WT cells (Tregs or Teff).
However preliminary data obtained from experiments using PSGL-1 deficient
cells were less clear. Effector T cells deficient of PSGL-1 produced higher amounts
of pro-inflammatory cytokines (GM-CSF, IFN-γ and TNF-α), explaining at least
partially the in vivo exacerbation of disease in PSGL-1 deficient mice (data not
shown). No significant differences were found between WT and PSGL-1 deficient
cells (both Tregs and Teff) for other cytokines. These results suggest that more
analysis is required for a better understanding of data obtained with PSGL-1 deficient
cells.
3.8 PSGL-1
-/- and FucT
-/- Tregs do not exert suppressor activity in mice with EAE
We next wanted to confirm the in vitro studies also in vivo in the context of
brain autoimmune diseases and we analyzed the effect of FucT-VII and PSGL-1
deficiencies on the induction of EAE. We first analyzed the ability of WT and PSGL-
1/FucT-VII deficient Tregs to ameliorate the disease course in C57BL/6J mice
immunized with the MOG35-55 peptide (active EAE). For this purpose, we isolated
CD4
+CD25
+ cells from WT or PSGL-1 deficient mice and transferred 2,5x10
6 cells in
immunized mice at day +7 post-immunization. Data obtained show that naïve PSGL-
1
-/-  Tregs  were  completely  unable  to  prevent  EAE,  whereas  naïve  WT  Tregs
ameliorated the disease course [Figure 15]. We have also obtained preliminary results
suggesting that also FucT-VII deficiency leads to a lack of inhibition of EAE (data
not shown). We obtained similar data when we used anti-CD3/IL-2 stimulated Tregs
[Fig. 16].  Taken together these in vivo data support the in vitro results and show a
key role for PSGL-1 and FucT-VII in the suppressor activity on EAE. Importantly,
recent preliminary results show that activated Tregs block EAE more efficiently when
compared to naive Tregs, suggesting that in vitro manipulation of Tregs might
increase their suppressor effect in vivo.30
3.9 FucT-VII and PSGL-1 are involved in the recruitment of Tregs in inflamed
central nervous system (CNS)
A. Measurement of the accumulation of 3H-glycerol labeled Tregs in vivo.
We have previously shown that PSGL-1 and FucT-VII are critical molecules
for the recruitment of lymphocytes into the inflamed brain (Piccio et al., J. Immunol.
2002; Battistini et al., Blood 2003; Piccio et al., J. Immunol. 2005). We next studied
the migration in various organs of WT and PSGL-1/FucT VII deficient Tregs in mice
with EAE. We first analyzed the migration of [
3H]-glycerol-labeled naïve Tregs,
injected at day +7 (pre-clinical phase) or +14 (disease onset) after immunization of
mice with the MOG35-55 peptide. We collected brain, spinal cords, draining lymph
nodes,  thymus,  liver,  spleen  and  blood.  Spinal  cord  was  considered  the  most
important organ in our analysis, as it represents the principal site of the inflammatory
autoimmune reactions against CNS parenchyma in MOG35-55 immunized mice. The
results obtained showed that naïve Tregs preferentially migrate in the preclinical
phase of disease when compared with the migration at disease onset (naïve Tregs
migrate two times more at day 7 compared to day 14) [Figure 17A]. In addition we
observed that also activated Tregs display a higher migration into the inflamed CNS
in the pre-clinical phase of disease [P<0.01. Fig. 17B]. These results are consistent
with: i) our previous data showing increased expression of endothelial selectins in the
preclinical phase of EAE when compared with disease onset (Piccio et al., 2002) and
with ii) flow cytometry results from Table I showing increased binding of E- and P-
selectin chimeras (consistent with an increased PSGL-1 functionality). When we
compared the migration of naïve versus activated Tregs we observed that activated T
cells are preferentially recruited in inflamed spinal cord both at day 7 and day14 post
immunization [Fig. 17C and D]. These results suggest that in vitro activation of Tregs
increase their delivery into the inflamed CNS. We next studied the role of PSGL-1
and FucT-VII in the migration of Tregs in vivo in mice with EAE. The results
obtained showed a drastic reduction of the migration of FucT-VII deficient Tregs,
while cells that lack PSGL-1 lost the ability to penetrate into the inflamed CNS
[P<0.0001. Fig. 17E]. Interestingly, we observed that at disease onset there is almost31
no inhibition of the migration using PSGL-1 and FucT-VII deficient cells [P<0.05.
Fig. 17E and F]. These results are consistent with the data described above showing a
preferential migration of Tregs in the preclinical phase of disease and with our
previous results showing that endothelial selectins are basically undetectable at
disease onset by in vivo staining (Piccio et al., 2002).
B.  Intravital  microscopy  analysis  of  Treg  adhesion  in  inflamed  brain
microcirculation
The formidable technical challenges associated with efforts to visualize brain
microcirculation in vivo have represented major obstacles to understanding how
leukocytes gain access into the brain during inflammation. Our initial efforts in this
area, using intravital microscopy, have implicated P-selectin glycoprotein ligand-1
(PSGL-1)  as  a  concomitant  of  recruitment  of  phenotypically  heterogeneous
autoreactive lymphocytes in inflamed brain venules (Piccio et al. J. Immunol. 2002;
Battistini et al., Blood 2003). In addition, it has been shown by our laboratory, as well
as by others, that endothelial E- and P-selectin, both PSGL-1 ligands, might be
involved  in  the  recruitment  of  leukocytes  in murine and human brains during
inflammatory diseases including EAE and MS.
We completed our study on the capacity of Tregs to migrate into the inflamed
brain  by  visualizing  and  analyzing  the  adhesive  events  in  inflamed  brain
microcirculation with intravital microscopy. We have previously shown that mice
treatment with TNF-α or LPS induces expression of P- and E-selectin, ICAM-1, and
VCAM-1 on brain endothelium (Piccio et al., 2002). This experimental model
resembles early inflammation during EAE, as we and others brought evidence that
brain endothelium expresses E- and P-selectin, ICAM-1 and VCAM-1 during early
inflammation in preclinical phase of autoimmune disease (Cannella et al., Lab
Investig. 1991; Piccio et al., J. Immunol. 2002; Kerfoot & Kubes. J. Immunol. 2002).
We studied the effect of PSGL-1 and FucT-VII deficiency on the behavior of Tregs in
inflamed brain venules. In agreement with our previous results obtained with TH1 and
encephalitogenic T cells, we observed a dramatic reduction of all adhesive events in32
cells deficient of PSGL-1 and FucT-VII [P<0.0001. Fig. 18 and 19] (Piccio et al.,
2005). These results confirm the data obtained at point A and clearly demonstrate that
PSGL-1  and FucT-VII are key molecules in the recruitment of Tregs into the
inflamed brain.33
4. Discussion
CD4+CD25+  Tregs  are  potent  immunoregulatory  cells  that  function
controlling immune responses. In fact, multiple animal models have convincingly
demonstrated the suppressive activity of Tregs in autoimmune, allergic diseases and
allograft rejection. The use of Tregs in the treatment of autoimmune pathologies such
as colitis, rheumatoid arthritis or multiple sclerosis is appealing and have the potential
to represent a major advance in the treatment of such diseases. It has been clearly
shown that Tregs are able to suppress EAE in various experimental models, including
MOG35-55-induced EAE in C57Bl/6 mice. Moreover, Viglietta et al. have recently
shown a significant decrease in the effector function of CD4
+CD25
high regulatory T
cells from the peripheral blood of MS patients as compared with healthy donors.
Thus, the enhancement of the number and activity of Tregs seems to represent an
obvious goal for the treatment of autoimmune diseases.
Recent data by Huehn et al. demonstrate that a subpopulation of CD4
+CD25
+
Tregs expressing αE integrin and able to bind E-and P-selectin (both PSGL-1 ligands)
preferentially migrates in sites of inflammation and blocks the development of
autoimmune arthritis. Data obtained in the present study suggested that PSGL-1
might be involved in the suppressor activity mediated by CD4
+CD25
+ cells during
MOG-induced EAE.
The results presented here started from the observation that transfer of T cells
lacking  FucT-VII  activity  or  PSGL-1  lead  to  an  increase  of  disease  severity
suggesting that FucT-VII and PSGL-1 are critical to protective mechanisms during
EAE.   We thus wanted to dissect the potential role of PSGL-1 and FucTs in the
suppressor activity mediated by CD4+CD25+ Foxp3+ regulatory T cells in vitro and
in vivo.
We studied the role of PSGL-1 and FucTs in in vitro the suppression of
effector  T  cell  functions,  which  requires  cell-cell  contact  between  Tregs  and
effettor/responder  T  cells.  FucT-VII  Tregs  showed  a  drastic  decrease  in  the
suppressor activity exerted on effector T cells, suggesting that glycans fucosylated on34
Tregs are involved in the suppression of proliferation. Moreover, proliferation of
effector cells (CD4+CD25-) deficient of FucT-VII in the presence of wt CD4+CD25+
T cells was 2-3 times less inhibited (depending on the responder/Treg ratio) when
compared with wt effector cells. Thus the lack of FucT-VII also on effector cells
significantly reverted the inhibitory effect on proliferation by Tregs. In contrast, we
observed no effect on the inhibition of proliferation when we used responder cells or
Tregs  deficient  in  FucT-IV.  Moreover,  analysis  of  cytokine  production  in
supernatants  collected  after  proliferation  assays  demonstrated  that  FucT-VII
deficiency either on Tregs or on effector cells strongly reverted the inhibitory effect
on  the  production  of  pro-inflammatory  cytokines,  but  not  on  Th2  and  anti-
inflammatory cytokines. These results show that FucT-VII has an important role in
the establishment of cell-cell contacts responsible for the suppressive activity of
Tregs. Our results indicate that FucT-VII activity is required on both sides: effector
and  regulatory  cells,  suggesting  that  similar  carbohydrate  structures  might  be
involved in these cell-cell interactions. These results might also suggest a mechanism
of control of TH1 cells by Tregs in vivo, as TH1 cells, but not TH2 cells, up-regulate
expression of FucT-VII and express functional PSGL-1. However, recent results by
Xu et al. suggest that CD4
+CD25
+ T cells are able to suppress both TH1 and TH2 cells
in vivo and in vitro. Tregs cells are heterogeneous cells and different mechanisms of
suppression may be involved in the inhibition of TH1 versus TH2 mediated responses.
Moreover, our results show that Tregs activation increase the inhibitory capability to
inhibit the proliferation of CD4
+CD25
-. These results correlate the increased adhesive
functionality of PSGL-1 (see Table I) to the increase of the suppression ability of
Tregs.
Proliferation of responder cells in the presence of CD4+CD25+ T cells
deficient in PSGL-1 was similar to wt Tregs, thus the lack of PSGL-1 had no effect
on the inhibition of proliferation by Tregs. However, the proliferation of effector cells
(CD4+CD25-) deficient in PSGL-1 in the presence of wt CD4+CD25+ T cells was
significantly reverted when compared with wt effector cells. Taken together these
results show that PSGL-1 has a role on effector T cells, but not on Tregs. The
discrepancy between the results obtained with cells deficient of FucTs versus cells35
deficient of PSGL-1 suggest that a not yet identified fucosylated molecule (not
PSGL-1) is involved in the cell-cell contacts responsible for suppressor activity
mediated by Tregs.
In addition, we observed that anti-L-selectin and anti-PSGL-1 blocking
antibodies revert immunosuppression by Tregs, suggesting that selectins and mucins
control, at least in part, cell-cell contact between Tregs and effector T cells. Taken
together, these data, together with EAE data described above, show that glycans are
critical for suppressive mechanisms regulating the immune responses. Recent data
obtained with the two-foton intravital microscopy technology show that Tregs exert
suppression in secondary lymphoid organs by blocking the interactions between
effector T cells and APCs (Tadokoro et al., JEM 2006; Tang et al., Nature Immunol.
2006). In fact, in order to validate our results obtained in vitro on the role of PSGL-1
and FucT-VII in cell-cell contact between Treg and responder cell, we are presently
performing in vivo two photon laser scanning microscopy in collaboration with Dr.
Mark Miller from Washington University (St. Louis).
Where Tregs act and how they migrate in vivo has hardly been studied so far
and a comprehensive analysis on trafficking properties of Tregs in vivo is still
lacking. [35]. In fact, the mechanisms involved in the migration of Tregs into the
brain are completely unknown. The main limitation in the identification of the
mechanisms controlling leukocyte recruitment in brain venules was the lack of
methods to directly visualize and analyze the interactions between leukocytes and
endothelium in microcirculation in live animal. To overcome this limitation our group
had  previously  set  up  a  new  intravital  microscopy  method  that  allows  the
visualization of brain microcirculation directly through the skull and analyze the
behavior of blood cells in mouse brain microvessels (Piccio et al., J. Immunol. 2002;
Battistini et al., Blood 2003; Pluchino et al., Nature 2005). Our results indicated that
after  activation,  the  capacity  of  Tregs  to  bind  P-  and  E-selectin  increases
significantly, suggesting that PSGL-1 become functional and able to bind its counter-
ligands. This data also suggest that activated CD4
+CD25
+ T cells may have increased
ability to migrate into sites of inflammation. In fact, confirming the data obtained in
vitro, our in vivo experiments using [
3H]-glycerol labeled Tregs show that activated36
Tregs are able to better migrate during the pre-clinical phase and at disease onset in
mice immunized with MOG35-55 peptide. Moreover, our results indicate that Tregs
are preferentially recruited during pre-clinical phase of disease (a time point when we
and others have shown that endothelial selectin are expressed on brain endothelium at
a higher level). Thus our results give important indication on the phenotype and the
kinetics of the migration of Tregs in mice with EAE.
The mucin PSGL-1 expressed by the leukocytes is classically responsible for efficient
tethering and rolling in vivo on either P- or E-selectin (Norman et al., 2000). We also
quantified the accumulation of Tregs obtained from PSGL-1 and FucT deficient mice
into the organs of animals in which we induced EAE with MOG35-55 peptide.
CD4+CD25+ T cells deficient in FucTs or PSGL-1 accumulated efficiently into the
lymphoid organs at all time points. However, the accumulation of CD4+CD25+ cells
deficient in PSGL-1 or FucT-VII was significantly decreased in the spinal cord of
EAE animals, suggesting that PSGL-1 and FucT-VII activity are involved in the
recruitment of CD4+CD25+ T cells into the inflamed brain. Moreover, data obtained
in intravital microscopy experiments performed in an experimental model that
mimics endothelial inflammation during pre-clinical phase of EAE showed that cells
from PSGL-1 and FucT-VII deficient mice have a dramatic decrease of the adhesive
interactions (tethering and rolling and arrest) in inflamed brain microcirculation when
compared with WT cells.  These in vivo results clearly demonstrate that PSGL-1 and
FucT-VII activity have a key role in the recruitment of Tregs in the inflamed CNS.
Taken together, our results allow us to demonstrate two different mechanisms
involving FucT-VII and PSGL-1 in the suppressor activity of Tregs. The first
mechanism is the recruitment of Tregs into the inflamed brain and it is based on our
evidence showing that both PSGL-1 and FucT-VII are important for the migration
capability of CD4+CD25+ cells. PSGL-1 and FucT-VII deficiencies dramatically
decrease the ability of Tregs to efficiently interact with inflamed endothelium
expressing  E-  and  P-selectin  and  to  migrate  to  inflamed  tissues.  The  second
mechanism is cell-cell contact necessary for the suppressor activity exerted by Tregs
on effector cells. While FucT-VII is critical and is required on both Tregs and effector
T cells, PSGL-1 has a role only when expressed on effector T cells.  This discrepancy37
suggest us that probably other fucosylated molecules are expressed on Tregs. In fact, .
in the last few years it has been shown that new classes of highly glycosylated
molecules such as T Cell Ig- and mucin-domain-containing molecules (TIMs) and
galectins are important for T cells activity, and we are presently exploring the
potential role of these molecules in cell-cell contact and migration required for
efficient suppressor activity by Tregs.
In conclusion the multiparametric approach used in this study allowed us to
analyze the role of molecules containing many carbohydrate branches (glycans) in the
control of suppressive action exerted by CD4+CD25+ cells during EAE, the animal
model of multiple sclerosis. The data obtained strongly indicate that PSGL-1 and the
fucosylation of its glycans by fucosultransferases (enzymes that add the carbohydrate
molecule fucose) are involved in the suppressor activity mediated by CD4+CD25+
cells during EAE. The project also used a sophisticated video-microscopy technique
that enabled direct visualization of the Treg cells as they circulate in blood vessels;
this technique helped us to clarify the role of PSGL-1 and FucTs in the selective
recruitment of Tregs cells into the inflamed brain. The knowledge of the molecular
mechanisms  controlling  the  recruitment  of Treg  into  the  brain  is  of  critical
importance, as potentially new therapies targeting migratory capabilities of T cells
should not interfere with the extravasation of Tregs into the brain. The project also
helped us to unveil the fact that activated Treg have a higher ability to migrate into
the inflamed microcirculation of the brain. Our results suggest that in vitro activated
Tregs could have a stronger therapeutic potential in demyelination diseases. Further
studies are needed to clarify whether in vitro Treg activation and manipulation have a
beneficial effect  also  on  disease  course.  The  knowledge  of  how to manipulate
CD4
+CD25
+ Tregs, in order to obtain cells with enhanced suppressive and migratory
capacity, may help to increase the inhibitory action exerted by regulatory T cells on
the autoimmune process.38
5. Figures and legends
Fig. 1: Top: Schematic depiction of the clinical evolution of MS by a clinical scale
(red line). The frequency of inflammatory events when studied by MRI (T1 lesions
with contrast showing blood-brain barrier opening, blue arrows); T2 lesion load
documenting all tissue damage (blue line); brain atrophy (green line). Pathology:
main pathological characteristics of MS. On the left, perivascular inflammation with
mononuclear cells and open blood-brain barrier; on the right, demyelinated areas
shown in light blue and white, and, on the far right, axonal transactions (blue onion
bulb-like structure) and segmental demyelination. MRI: Typical MRI characteristics.
On the left, T1-weighted image with Gadolinium contrast enhancement. White
lesions indicate areas of fresh inflammation and open blood-brain barrier. T2-
weighted image shows the CSF-filled ventricles in white and MS lesions in the brain
parenchyma. On the right, brain atrophy with widened lateral ventricles and cortical
sulci. [Figure adapted from Sospedra M. and Martin R., Annu. Rev. Immunol. (2005)].39
Fig. 2: Inflammation and immune mechanisms in multiple slerosis. a. Multiple
sclerosis is probably induced by the generation of TH1-type myelin-reactive cells
from  precursor  cells  (THP),  which  are  presumably  triggered  by  cross-reactive
antigens, such as viruses, in the context of co-stimulatory molecules and IL-12. TH1-
type cells directed against myelin migrate into the nervous system where they re-
encounter myelin antigens presented by microglia and are re-stimulated to initiate a
destructive inflammatory cascade. b. Immune therapy involves the induction of anti-
inflammatory regulatory T cells (TH2, TH3, TR1, CD25
+ cells) that secrete anti-
inflammatory cytokines, such as IL-4, IL-10 and TGF-β. Regulatory cells, that act by
cell/cell contact (CD25
+ cells), inhibit TH1 responses in the periphery and/or migrate
to the CNS, where they are re-stimulated by local microglia cells and inhibit or
suppress the local inflammatory cascade in the CNS.40
Fig. 3: The multistep model of leukocyte migration through the endothelium.
The process known as "capture" or "tethering" represents the first contact of a
leukocyte with the activated endothelium. Subsequent rolling consists of reversible
adhesive interactions and is mediated by selectins, integrins and their counterligands:
mucins and immunoglobulins. During an early inflammatory response, P- and E-
selectin on endothelial cells are primary molecules for capture and initiation of slow,
inflammatory rolling. During the rolling, the leukocyte is activated by chemokines
released from the endothelium; via G-protein pathways, the production of integrins
on the leukocyte is up-regulated. Integrins interact with their counter-ligands on
endothelial cells, permitting the arrest of the cells. The last step will be the migration
of the leukocyte through the endothelium in the tissue. [Figure adapted from Luster
A. D. et al., Nat. Immunol. (2005)].41
Fig. 4. Treg compartmentalization determines suppressive activity in vivo.
Peripheral antigen, transported from the inflamed site to the local draining lymph
node (b) by professional antigen-presenting cells (APCs), leads to expansion and
differentiation of naive T cells. This priming step is under the control of naive-like
Tregs, which express high levels of L-selectin (CD62L) and CCR7. This enables
efficient migration of these recirculating Tregs into lymphoid organs via the high
endothelial venules expressing ligands for L-selectin and presenting CCR7 ligands on
their surface. The chemokine receptor CCR4 might have a role in the interaction
between  naive-like  Tregs  and  APCs  within  lymph  tissues.  (a)  By  contrast,
effector/memory-like Tregs  display  an  inflammation-seeking  phenotype  by  the
expression of diverse CCRs, E/P-selectin ligands, β1-integrins and high levels of
LFA-1. This enables an efficient entry into inflamed sites because it is expected that
activated endothelia will express high levels of E-selectin, P-selectin, ICAM-1 and
VCAM-1, and will present inflammatory chemokines on their surface. Thereby, these
inflammation-seeking Tregs are predestinated to control the inflammatory action of
effector cells at peripheral sites. [Figure adapted from Huehn J. and Hamann A.,
Trends Immunol. (2005)].42
Fig. 5: Intravital microscopy in mouse brain microcirculation. A. Ligations
performed to exclude the arrival of fluorescent cells into the non-cerebral vessels. B.
Mouse scalp is reflected and a coverslip will be applied and fixed with silicon grease.
A  round  camera  is  attached  on  the  coverslip  and  filled  with  water. C. The
characteristic convex origin of superficial cerebral venules (arrows) is due to the
emergence of the vessel on the brain surface from the more profound layers. Cerebral
vessels are labeled with fluorescent dextran. D. Intravital microscopy equipment (see
below).
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Fig. 6: PSGL-1 deficiency increases disease severity in actively-induced EAE.
The figure represents the mean results obtained from 4 different experiments of
actively-induced EAE with MOG35-55 peptide. (P<0.01).
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Fig. 7: PSGL-1 deficiency induces increased severity in passively-induced EAE.
MOG specific T cell lines, produced from spleen and draining lymph nodes of WT
and PSGL-1
-/- animals immunized with MOG35-55 peptide were transferred in WT
recipients. PSGL-1 deficient T cells were able to transfer a more severe disease when
compared to wt cells.44
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Fig. 8: FucT-VII deficiency increased disease severity in passively-induced EAE.
MOG specific T cell lines were produced from spleen and draining lymph nodes of
WT and FucT
-/- animals immunized with MOG35-55 peptide, and then transferred in
WT recipient mice. Note the increased disease severity observed when we transferred
T cells deficient of FucT-VII, while results obtained with FucT-IV
-/- cells were not
statistically significant.45
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Fig. 9: Proliferative response to MOG35-55 peptide in lymph node cells from
FucT-IV
-/-,  FucT-VII
-/-  and  PSGL-1
-/-  mice.  MOG35-55  specific  T  cells  were
produced as described at “Materials and Methods”. 5x10
5 CD4
+ T cells isolated from
spleens (A) or from peripheral lymph nodes (B) were cultured in a volume of 200
µl/well with MOG 0 (control) - 5 - 30 µg/ml or PHA 1 µg/ml. 3 wells/condition were
used. No significant differences were observed between the T cell populations
isolated from wt mice or mice deficient in PSGL-1 and FucTs.
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Fig.10: Analysis of cytokine production by MOG35-55 auto-reactive T cells from
WT  and  PSGL-1/FucTs  deficient  mice. 5x10
5  CD4+  T  cells  isolated  from
peripheral lymph nodes and spleens were cultured in a volume of 200 µl/well with
MOG35-55 peptide 30 µg/ml. The results are expressed as mean cytokine production of
3 wells/condition. As expected, the production of IL-4 was very low consistent with a
Th1 phenotype of the encephalitogenic T cells. No significant differences were
observed between the auto-reactive T cell populations.47
Fig.  11:  The  suppressive  effect  on  the  proliferative response: comparison
between stimulated and naïve Tregs. Tregs stimulated with anti-CD3 (5 µg/ml) and
IL-2 (100 U/ml) had increased suppressor activity in inhibiting the proliferation of
CD4
+CD25
- responder cells. Co-cultures were performed using different Treg/Teff
cell ratios.
Fig. 12: The effect of adhesion blocking mAbs on the suppressor activity of
stimulated Tregs. Co-cultures were made with CD4+CD25+Tregs and CD4
+CD25
-
T cells (responder cells) for 72h in the presence of APCs and with 1µg/ml anti-CD3.
The results are expressed as % of CD4
+CD25
- T cells proliferation. CD4
+CD25
- /
CD4
+CD25
+ T cells ratio was 1/1. The following antibodies were used: anti-L-
selectin (Mel-14), anti-α4 integrins (PS/2), anti-PSGL-1 (4RA10) and a control anti-
rat isotype mAb. The results show that L-selectin and PSGL-1 are involved in the
suppression exerted by Tregs on responder cell proliferation. (*: P<0.001).
0
5
10
15
20
25
30
35
40
45
50
%
 
o
f
 
c
o
n
t
r
o
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
Treg/Teff 1/8 1/1
6
1/32 1/4
Naive CD4
+CD25
+
Stimulated CD4
+CD25
+
1/8 1/1
6
1/32 1/4
0
5
10
15
20
25
30
35
40
45
CTR anti-L-sel anti-PSGL-1 anti-L-sel and
anti-PSGL-1
anti-VLA-4
%
 
o
f
 
c
o
n
t
r
o
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
*  *
*48
CD25+WT
+
CD25-WT
CD25+FucT-VII-/-
+
CD25-WT
CD25+WT
+
  CD25-FucT-VII-/-
CD25+FucTVII-/-
+
  CD25-FucT-VII-/-
Teff/Treg
%
 
o
f
 
C
D
4
+
C
D
2
5
-
 
T
 
c
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
A
CD25+WT
+
CD25-WT
CD25+FucT-IV-/-
+
CD25-WT
CD25+WT
+
  CD25-FucT-IV-/-
CD25+FucT-IV-/-
+
  CD25-FucT-IV-/-
Teff/Treg
%
 
o
f
 
C
D
4
+
C
D
2
5
-
 
T
 
c
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
B49
Fig. 13 (pag. 48 and 49): The effect of FucTs and PSGL-1 deficiencies on the
suppressor activity of CD4
+CD25
+ regulatory T cells. The experiments were
performed with naïve Tregs. Different ratio Tregs/Teff ratios were used. Data are
shown as percentage of proliferation compared with a control (100%) represented by
CD4
+CD25
-  from  the  recipient  mice.  To  note,  FucT-VII  deficiency  leads  to  a
reduction of suppressor activity when present on Tregs or responder cells or both
populations (A). PSGL-1 expression is requires only on effector cells for efficient
cell-cell contact (C) (*P<0.01). No significant effects are associated with FucT-IV
deficiency (B).
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Fig. 14 (pag. 50 and 51). The effect of FucT-VII deficiency on the regulation of
cytokine  production  by  Tregs. Data were obtained with in Multiplex assays
(BioRad) on supernatants collected from co-cultures performed as described for
Figure 13 (proliferation assays). Effects of FucT-VII deficiency on GM-CSF, IFN-γ,
and IL-2 secretion are shown in A (P<0.01). The effect of FucT-VII KO on IL-4, IL-
5, and IL-10 secretion is shown in B.
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Fig.  15:  Effect  of  PSGL-1  deficiency  on  naïve  Tregs  suppression  of  EAE.
C57BL/6J mice immunized with MOG35-55 peptide (active EAE) were injected i.v. at
day +7 post-immunization with 2,5x10
6 Tregs from WT or PSGL-1 deficient  mice.
Data showed are from one representative experiment with 6 mice per condition from
a series of three with similar results. We observed a complete lack of suppression by
PSGL-1 deficient Tregs when compared with WT Tregs (P<0.02 when compared
with WT Tregs-transplanted group). Interestingly, we observed a higher disease score
in animals injected with Tregs from PSGL-1
-/- mice after day +25 post-immunization.53
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Fig. 16: The effect of stimulated PSGL-1 deficient Tregs on EAE. C57BL/6J mice
immunized with MOG35-55 protocol (active EAE) were injected i.v. at day +7 post-
immunization with 2,5x10
6 anti-CD3/IL-2-stimulated Tregs from WT or PSGL-1
deficient mice. Data showed are from one experiment with 6 mice per condition. As
shown for naïve Tregs, animals treated with PSGL-1 deficient Tregs displayed a
higher mean disease clinical score than controls and mice transplanted with WT
Tregs (P<0.01).54
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Fig. 17 (pag. 54 and 55): migration ability of Tregs in vivo. WT C57BL/6J mice
were immunized with the MOG35-55 peptide. Tregs from WT, FucT-VII-/- or PSGL-
1-/- donor mice were used. 2,5x10
6 [
3H]-glycerol-labeled naïve WT Tregs (A) or
activated Tregs (B) were injected at day 7 and day 14 post immunization. The
migration of naïve versus stimulated Tregs was compared at day 7 (C) and at day 14
(D) post immunization. The effect of PSGL-1 and FucT-VII deficiency was studied
with naïve Tregs at day 7 (E) and day 14 (F) post immunization. In all experiments
mice were sacrificed at 24h after Treg administration and then were perfused with
PBS through the left ventricle. Organs were collected, sonicated and added in
scintillation liquid; the radioactivity was evaluated with a β-counter. The results show
that naïve and activated Tregs better migrate in the pre-clinical phase of disease (A
and B) (*P<0.01), while activated T cells have increased migration capacity when
compared to naïve Tregs (C, D) (*P<0.01). A clear role for PSGL-1 and FucT-VII is
seen in the inflamed spinal cord in the pre-clinical phase of disease (E) (**P<0.0001
in E and **P<0.05 in F). For each point, data are from one representative experiment
with 3-4 mice/condition from a series of two.57
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Fig. 18: Analysis of Tregs adhesion ability with intravital microscopy. Tregs from
WT,  PSGL-1
-/-  and  FucT-VII
-/-  mice  were  stimulated  with  the  anti-CD3/IL-2
protocol. After 3 days, 2,5x10
6 cells were labeled with CMTMR or CMFDA (see
Materials  and  methods)  and  injected  via-catheter  in  a  7  weeks-old  SJL  mice,
previously  treated  with  12  µg  of  LPS  in  order  to  subacutely  inflame  brain
endothelium  (6h  before  the  intravital  microscopy  experiment).  The  model  of
endothelium activation used here mimics the inflammatory conditions shown during
pre-clinical phase of EAE (Piccio et al., 2002). Data are expressed as percentage of
total cells observed. The results are the average of 2 experiments, analyzing 2-3
venules per brain. Tregs from PSGL-1 and FucT-VII deficient mice presented a
dramatic  reduction  in  the  ability  to  adhere  to  endothelium  in  inflamed  brain
microcirculation (P<0.0001).58
  
Fig. 19: Intravital microscopy imaging. To note, CMFDA-labeled WT Tregs highly
adhere  on  inflamed  brain  endothelium  (left),  while  CMTMR-labeled  PSGL-1
deficient Tregs (right) display an almost complete inhibition of the adhesion. Cells
are the white spots inside blood vessels labeled with fluorescent dextrans.59
6. Table and legend
α4 integrins LFA-1 PSGL-1 L-selectin CD44 P-sel. Chimera E-sel. Chimera
             
naive Tregs 53% 99% 96% 51% 88% 4% 0,70%
% (MFI) (21.14) (54.2) (92.27) (33.64) (63.31) (273.97) (77.87)
stimulated Tregs 42% 99% 98% 75% 93% 23.5% 2,40%
% (MFI) (14.93) (59.86) (116.47) (52.79) (55.64) (511.41) (308.86)
Table  I.  Tregs  display  higher  binding  activity  to  E-  and  P-selectin  after
activation with anti-CD3 mAb and IL-2.60
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